Hyzaar: Effective Blood Pressure and Heart Protection Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.21 (0%) | 🛒 Add to cart |
| 60 | $1.51 | $104.42 $90.37 (13%) | 🛒 Add to cart |
| 90 | $1.43 | $156.63 $128.52 (18%) | 🛒 Add to cart |
| 120 | $1.38 | $208.85 $165.67 (21%) | 🛒 Add to cart |
| 180 | $1.34 | $313.27 $241.98 (23%) | 🛒 Add to cart |
| 270 | $1.32 | $469.90 $356.44 (24%) | 🛒 Add to cart |
| 360 | $1.31
Best per pill | $626.54 $471.91 (25%) | 🛒 Add to cart |
Hyzaar is a prescription medication combining two active ingredients, losartan and hydrochlorothiazide, designed for the management of hypertension. It functions through a dual mechanism: losartan blocks angiotensin II receptors to relax blood vessels, while hydrochlorothiazide reduces fluid volume, collectively lowering blood pressure and decreasing cardiovascular strain. This combination is often prescribed when monotherapy is insufficient, offering a comprehensive approach to hypertension control and reducing the risk of stroke and heart attack in patients with left ventricular hypertrophy.
Features
- Contains losartan potassium and hydrochlorothiazide in fixed-dose combinations (e.g., 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg)
- Angiotensin II receptor blocker (ARB) and thiazide diuretic in a single tablet
- Once-daily oral administration for consistent 24-hour blood pressure control
- Available in film-coated tablets for ease of swallowing
- Manufactured under strict pharmaceutical quality standards
Benefits
- Provides synergistic blood pressure lowering greater than either component alone
- Reduces the risk of stroke in patients with hypertension and left ventricular hypertrophy
- Helps protect kidney function in hypertensive patients with type 2 diabetes and proteinuria
- Decreases cardiovascular mortality and morbidity associated with chronic hypertension
- Minimizes pill burden through combination therapy
- Offers flexible dosing options to accommodate individual patient needs
Common use
Hyzaar is primarily indicated for the treatment of hypertension in patients for whom combination therapy is appropriate. It is commonly prescribed when blood pressure remains uncontrolled with losartan or hydrochlorothiazide monotherapy. The medication is also used to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, as demonstrated in clinical trials. Healthcare providers may initiate Hyzaar in patients who require additional blood pressure control beyond what single-agent therapy can provide, particularly those with volume overload or resistant hypertension.
Dosage and direction
The recommended starting dose of Hyzaar is one tablet (50 mg losartan/12.5 mg hydrochlorothiazide) once daily. For patients who do not achieve adequate blood pressure control after 2-3 weeks, the dosage may be increased to two tablets of 50 mg/12.5 mg once daily or one tablet of 100 mg/12.5 mg once daily. The maximum recommended daily dose is 100 mg losartan/25 mg hydrochlorothiazide. Hyzaar may be taken with or without food, preferably at the same time each day to maintain consistent therapeutic levels. Dose titration should be based on individual patient response and tolerability, with consideration given to the patient’s renal function and electrolyte status.
Precautions
Patients taking Hyzaar should have regular monitoring of blood pressure, renal function, and serum electrolytes, particularly potassium, sodium, and magnesium. Caution is advised in patients with impaired renal function, as hydrochlorothiazide may precipitate azotemia. Those with hepatic impairment require careful monitoring due to possible alterations in losartan metabolism. Hyzaar may cause dizziness or lightheadedness, especially during initial therapy or dose increases, potentially affecting the ability to operate machinery or drive. Adequate hydration should be maintained, especially in elderly patients and during hot weather, to prevent volume depletion. Patients with asthma or allergy history may experience exacerbated symptoms due to hydrochlorothiazide component.
Contraindications
Hyzaar is contraindicated in patients with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It must not be used in patients with anuria or severe renal impairment (creatinine clearance <30 mL/min). The medication is contraindicated in patients with refractory hypokalemia, hyponatremia, or hypercalcemia. Use is prohibited during pregnancy, particularly in the second and third trimesters, due to potential fetal harm. Concomitant use with aliskiren in patients with diabetes is contraindicated. Patients with history of angioedema related to previous angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy should not receive Hyzaar.
Possible side effect
Common side effects include dizziness (3.5%), upper respiratory infection (2.1%), cough (2.0%), and fatigue (1.5%). Less frequently, patients may experience orthostatic hypotension, gastrointestinal disturbances such as diarrhea or nausea, and muscle cramps. Hydrochlorothiazide component may cause photosensitivity, electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia), and hyperuricemia. Rare but serious adverse effects include angioedema, hepatotoxicity, pancreatitis, and blood dyscrasias. Some patients may develop increased serum creatinine or blood urea nitrogen levels. Clinical monitoring is essential to detect and manage these potential effects promptly.
Drug interaction
Hyzaar may interact with several medication classes. Concomitant use with other antihypertensive agents may potentiate blood pressure lowering effects. Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the antihypertensive efficacy and increase renal impairment risk. Lithium levels may increase when co-administered with Hyzaar, requiring close monitoring. Potassium-sparing diuretics or potassium supplements may lead to hyperkalemia. The hypoglycemic effect of insulin and oral antidiabetic agents may be enhanced. Cholestyramine and colestipol may reduce hydrochlorothiazide absorption. Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. Digitalis toxicity may be exacerbated by hypokalemia induced by hydrochlorothiazide.
Missed dose
If a dose of Hyzaar is missed, it should be taken as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for the missed one, as this may increase the risk of adverse effects such as hypotension or electrolyte disturbances. Consistency in dosing is important for maintaining stable blood pressure control, so patients should establish a routine for medication administration. If multiple doses are missed, patients should contact their healthcare provider for guidance rather than attempting to compensate with larger subsequent doses.
Overdose
Hyzaar overdose may manifest as symptoms related to its individual components. Losartan overdose may cause hypotension and tachycardia, while hydrochlorothiazide overdose may lead to profound electrolyte disturbances, dehydration, and circulatory collapse. Symptoms may include dizziness, syncope, gastrointestinal disturbances, and renal impairment. Management involves supportive care with close monitoring of vital signs, electrolyte levels, and renal function. Gastric lavage or activated charcoal may be considered if ingestion occurred recently. Specific treatment should address symptomatic hypotension with intravenous fluids and, if necessary, vasopressors. Electrolyte abnormalities should be corrected appropriately. There is no specific antidote for Hyzaar overdose; hemodialysis is not effective for removing losartan but may help correct electrolyte imbalances.
Storage
Hyzaar tablets should be stored at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication must be kept in its original container with the lid tightly closed to protect from moisture and light. Tablets should not be stored in bathroom cabinets or other areas with high humidity. Keep out of reach of children and pets. Do not use Hyzaar beyond the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs or by mixing with undesirable substances before disposal in household trash.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Hyzaar is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient responses may vary, and treatment decisions should be based on a healthcare provider’s assessment of the specific clinical situation. Patients should not initiate, adjust, or discontinue Hyzaar without consulting their physician. The complete prescribing information contains additional details about warnings, precautions, and adverse reactions. Healthcare providers should reference the full prescribing information before initiating therapy.
Reviews
Clinical studies demonstrate that Hyzaar provides effective blood pressure control in approximately 70-80% of patients with stage 1 and 2 hypertension. The LIFE trial showed significant stroke risk reduction in hypertensive patients with left ventricular hypertrophy compared to atenolol-based therapy. Many patients report satisfactory blood pressure management with once-daily dosing convenience. Some reviews note the combination therapy reduces pill burden compared to taking two separate medications. However, some patients report experiencing side effects such as dizziness or fatigue, particularly during therapy initiation. Overall, Hyzaar is considered an effective second-line option for hypertension management when monotherapy provides insufficient control.